With this acquisition, Sanofi aims to further strengthen its core R&D areas of autoimmune and allergic diseases. The move will also provide full control of the brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis which is expected to make commercialisation more efficient and eliminate royalty payments in the future.

With an aim to accelerate the adoption of continuous pharmaceutical manufacturing, Emerson and Integra CMS have signed a joint agreement. The deal is expected to expand pioneering research and improve manufacturing cost and quality in the industry.

KBR and Johnson Matthey (JM) have entered into a contract to license an innovative ammonia-methanol co-production process technology which is capable of merging their unique ammonia and methanol technologies respectively.

Evonik will be conducting the free weekly webinar series every Tuesday from October 6 – December 8, 2020. Each session will focus on key formulation, process and production challenges for complex oral and parenteral drug products.

With an aim to strengthen its position in Expancel expandable microspheres, Nouryon has plans to invest in a new US plant in Green Bay, Wisconsin. The facility is expected to meet the growing demand of Expancel across the globe.

Korsch’s new X 3 Tablet Press incorporates production capabilities and versatility that were traditionally limited to large-scale production machines.

The Spanish pharma firm, Faes Farma is making use of its acquired Syrris Asia system to develop novel synthesis pathways for new and existing APIs. The unique system will enable the company to perform reactions that would otherwise be too dangerous to perform in a batch set-up.

Together, the MOL Group and Meraxis intend to develop and produce high-quality recycle-based compounds. Under this deal, Meraxis will supply the MOL Group with high-quality, post-consumer recycled materials which will be combined with the firm’s virgin polyolefin resins.

With the mega investment, Merck will expand its high-potent active pharmaceutical ingredient (Hpapi) and antibody-drug conjugates (ADC) manufacturing capabilities. The new 6,500-sq m facility is expected to be one of the largest Hpapi manufacturing facilities capable of handling single-digit nanogram occupational exposure limit materials.

Lux Research’s new report titled ‘The Chemicals and Materials Company of 2040’ states that over the next 20 years, the chemicals and materials industries will change drastically due to climate change and the digital transformation. The sectors will also be forced to adopt new skills and develop new goals to stay competitive in the market.